{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:03:30Z","timestamp":1784124210182,"version":"3.55.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12321-9","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:12:30Z","timestamp":1784117550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From barrier to trigger: leveraging tumor hypoxia for precise control of CAR-T cell activity"],"prefix":"10.1007","volume":"53","author":[{"given":"Parisa","family":"Pedram Rad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Reyhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9085-4656","authenticated-orcid":false,"given":"Mohammadreza","family":"Dashti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"12321_CR1","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D (2021) Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther 221:107753","journal-title":"Pharmacol Ther"},{"issue":"5","key":"12321_CR2","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","volume":"45","author":"L Short","year":"2024","unstructured":"Short L, Holt RA, Cullis PR, Evgin L (2024) Direct in vivo CAR T cell engineering. Trends Pharmacol Sci 45(5):406\u2013418","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"12321_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","volume":"10","author":"M Tufail","year":"2025","unstructured":"Tufail M, Jiang CH, Li N (2025) Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduct Target Ther 10(1):227","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"12321_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi F, Motavalli R, Safonov VA, Thangavelu L, Yumashev AV, Alexander M et al (2021) CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther 12(1):81","journal-title":"Stem Cell Res Ther"},{"issue":"8","key":"12321_CR5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc.2017.51","volume":"17","author":"M De Palma","year":"2017","unstructured":"De Palma M, Biziato D, Petrova TV (2017) Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer 17(8):457\u2013474","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"12321_CR6","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.molcel.2020.05.034","volume":"78","author":"JE Bader","year":"2020","unstructured":"Bader JE, Voss K, Rathmell JC (2020) Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. Mol Cell 78(6):1019\u20131033","journal-title":"Mol Cell"},{"issue":"5","key":"12321_CR7","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P et al (2014) PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211(5):781\u2013790","journal-title":"J Exp Med"},{"key":"12321_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118389","volume":"259","author":"A Giatromanolaki","year":"2020","unstructured":"Giatromanolaki A, Kouroupi M, Pouliliou S, Mitrakas A, Hasan F, Pappa A et al (2020) Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways. Life Sci 259:118389","journal-title":"Life Sci"},{"issue":"5","key":"12321_CR9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ccell.2017.10.003","volume":"32","author":"A Palazon","year":"2017","unstructured":"Palazon A, Tyrakis PA, Macias D, Veli\u00e7a P, Rundqvist H, Fitzpatrick S et al (2017) An HIF-1\u03b1\/VEGF-A axis in cytotoxic T cells regulates tumor progression. Cancer Cell 32(5):669\u201383. e5","journal-title":"Cancer Cell"},{"key":"12321_CR10","doi-asserted-by":"crossref","unstructured":"Berahovich R, Liu X, Zhou H, Tsadik E, Xu S, Golubovskaya V et al (2019) Hypoxia Selectively Impairs CAR-T Cells In Vitro. Cancers (Basel). ;11(5)","DOI":"10.3390\/cancers11050602"},{"key":"12321_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1357801","volume":"14","author":"AR Panahi Meymandi","year":"2024","unstructured":"Panahi Meymandi AR, Akbari B, Soltantoyeh T, Shahosseini Z, Hosseini M, Hadjati J et al (2024) PX-478, an HIF-1\u03b1 inhibitor, impairs mesoCAR T cell antitumor function in cervical cancer. Front Oncol 14:1357801","journal-title":"Front Oncol"},{"key":"12321_CR12","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3389\/fimmu.2020.01906","volume":"11","author":"YN Liu","year":"2020","unstructured":"Liu YN, Yang JF, Huang DJ, Ni HH, Zhang CX, Zhang L et al (2020) Hypoxia Induces Mitochondrial Defect That Promotes T Cell Exhaustion in Tumor Microenvironment Through MYC-Regulated Pathways. Front Immunol 11:1906","journal-title":"Front Immunol"},{"issue":"1","key":"12321_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-07278-5","volume":"23","author":"M Zhou","year":"2025","unstructured":"Zhou M, Xu L, Hu J, Chen W, Hong J, Wang M et al (2025) Metabolic reprogramming through PIM3 inhibition reverses hypoxia-induced CAR-T cell dysfunction in solid tumors. J Transl Med 23(1):1230","journal-title":"J Transl Med"},{"issue":"1","key":"12321_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen Z, Han F, Du Y, Shi H, Zhou W (2023) Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Therapy 8(1):70","journal-title":"Signal Transduct Target Therapy"},{"key":"12321_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2020.12.004","volume":"500","author":"H Rostamian","year":"2021","unstructured":"Rostamian H, Fallah-Mehrjardi K, Khakpoor-Koosheh M, Pawelek JM, Hadjati J, Brown CE et al (2021) A metabolic switch to memory CAR T cells: Implications for cancer treatment. Cancer Lett 500:107\u2013118","journal-title":"Cancer Lett"},{"key":"12321_CR16","doi-asserted-by":"crossref","unstructured":"Abou Khouzam R, Brodaczewska K, Filipiak A, Zeinelabdin NA, Buart S, Szczylik C et al (2021) Tumor Hypoxia Regulates Immune Escape\/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies. ;Volume 11\u20132020","DOI":"10.3389\/fimmu.2020.613114"},{"issue":"1","key":"12321_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/emm.2004.1","volume":"36","author":"JW Lee","year":"2004","unstructured":"Lee JW, Bae SH, Jeong JW, Kim SH, Kim KW (2004) Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. Exp Mol Med 36(1):1\u201312","journal-title":"Exp Mol Med"},{"key":"12321_CR18","doi-asserted-by":"crossref","unstructured":"Wicks EE, Semenza GL (2022) Hypoxia-inducible factors: cancer progression and clinical translation. J Clin Investig. ;132(11)","DOI":"10.1172\/JCI159839"},{"issue":"1","key":"12321_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.gde.2009.10.009","volume":"20","author":"GL Semenza","year":"2010","unstructured":"Semenza GL (2010) HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20(1):51\u201356","journal-title":"Curr Opin Genet Dev"},{"issue":"4","key":"12321_CR20","doi-asserted-by":"publisher","first-page":"F898","DOI":"10.1152\/ajprenal.00335.2010","volume":"300","author":"RK Basu","year":"2011","unstructured":"Basu RK, Hubchak S, Hayashida T, Runyan CE, Schumacker PT, Schnaper HW (2011) Interdependence of HIF-1\u03b1 and TGF-\u03b2\/Smad3 signaling in normoxic and hypoxic renal epithelial cell collagen expression. Am J Physiol Ren Physiol 300(4):F898\u2013905","journal-title":"Am J Physiol Ren Physiol"},{"issue":"4","key":"12321_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3892\/ol.2022.13489","volume":"24","author":"D Ribatti","year":"2022","unstructured":"Ribatti D (2022) Immunosuppressive effects of vascular endothelial growth factor. Oncol Lett 24(4):369","journal-title":"Oncol Lett"},{"key":"12321_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.837230","volume":"13","author":"C Sun","year":"2022","unstructured":"Sun C, Wang B, Hao S (2022) Adenosine-A2A receptor pathway in cancer immunotherapy. Front Immunol 13:837230","journal-title":"Front Immunol"},{"key":"12321_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1711328","volume":"16","author":"HC Ertl","year":"2025","unstructured":"Ertl HC (2025) Metabolism of tumor infiltrating T cells. Front Immunol 16:1711328","journal-title":"Front Immunol"},{"key":"12321_CR24","first-page":"S1045","volume":"25","author":"B Tiwari","year":"2025","unstructured":"Tiwari B, Sapkota S, Chaulagain P (2025) CT-1171: Hypoxia in the Tumor Microenvironment Impairs CAR T-Cell Cytotoxicity via Metabolic Constraints. Clin Lymphoma Myeloma Leuk 25:S1045","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"12321_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/0008-5472.CAN-23-1038","volume":"84","author":"X Zhu","year":"2024","unstructured":"Zhu X, Chen J, Li W, Xu Y, Shan J, Hong J et al (2024) Hypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors. Cancer Res 84(1):84\u2013100","journal-title":"Cancer Res"},{"issue":"3","key":"12321_CR26","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/s44318-024-00319-7","volume":"44","author":"H Estephan","year":"2025","unstructured":"Estephan H, Tailor A, Parker R, Kreamer M, Papandreou I, Campo L et al (2025) Hypoxia promotes tumor immune evasion by suppressing MHC-I expression and antigen presentation. EMBO J 44(3):903\u2013922","journal-title":"EMBO J"},{"key":"12321_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.844866","volume":"13","author":"BC Taylor","year":"2022","unstructured":"Taylor BC, Balko JM (2022) Mechanisms of MHC-I downregulation and role in immunotherapy response. Front Immunol 13:844866","journal-title":"Front Immunol"},{"issue":"5","key":"12321_CR28","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/cells14050320","volume":"14","author":"B Zhang","year":"2025","unstructured":"Zhang B, Wu J, Jiang H, Zhou M (2025) Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy. Cells [Internet] 14(5):320 p.]","journal-title":"Cells [Internet]"},{"issue":"12","key":"12321_CR29","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1128\/MCB.21.12.3995-4004.2001","volume":"21","author":"E Laughner","year":"2001","unstructured":"Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21(12):3995\u20134004","journal-title":"Mol Cell Biol"},{"issue":"1","key":"12321_CR30","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s40001-024-02073-2","volume":"29","author":"AR Devan","year":"2024","unstructured":"Devan AR, Nair B, Pradeep GK, Alexander R, Vinod BS, Nath LR et al (2024) The role of glypican-3 in hepatocellular carcinoma: Insights into diagnosis and therapeutic potential. Eur J Med Res 29(1):490","journal-title":"Eur J Med Res"},{"key":"12321_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01000","volume":"10","author":"B Nazha","year":"2020","unstructured":"Nazha B, Inal C, Owonikoko TK (2020) Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy. Front Oncol 10:1000","journal-title":"Front Oncol"},{"key":"12321_CR32","doi-asserted-by":"crossref","unstructured":"Wilde AAM, Semsarian C, M\u00e1rquez MF, Shamloo AS, Ackerman MJ, Ashley EA et al (2022) European Heart Rhythm Association (EHRA)\/Heart Rhythm Society (HRS)\/Asia Pacific Heart Rhythm Society (APHRS)\/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace: European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 24(8):1307\u20131367","DOI":"10.1093\/europace\/euac106"},{"key":"12321_CR33","doi-asserted-by":"crossref","unstructured":"Liikanen I, Lauhan C, Quon S, Omilusik K, Phan AT, Bartrol\u00ed LB et al (2021) Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8\u2009+\u2009T cells. J Clin Investig. ;131(7)","DOI":"10.1172\/JCI143729"},{"issue":"26","key":"12321_CR34","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127(26):3321\u201330","journal-title":"Blood"},{"issue":"3","key":"12321_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2021.100723","volume":"2","author":"P Kosti","year":"2021","unstructured":"Kosti P, Larios-Martinez KI, Maher J, Arnold JN (2021) Generation of hypoxia-sensing chimeric antigen receptor T cells. STAR Protoc 2(3):100723","journal-title":"STAR Protoc"},{"issue":"1","key":"12321_CR36","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2025.2579069","volume":"58","author":"H Li","year":"2025","unstructured":"Li H, Xiong J, Wang C, Hu L, Wang YB, Ping QR et al (2025) CAR-T cell therapy for solid tumors: HIF-1\u03b1 as a potential enhancement strategy. Autoimmunity 58(1):2579069","journal-title":"Autoimmunity"},{"key":"12321_CR37","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.omto.2023.08.009","volume":"30","author":"W Zhou","year":"2023","unstructured":"Zhou W, Miao J, Cheng Z, Wang Z, Wang J, Guo H et al (2023) Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL. Mol Ther Oncolytics 30:216\u2013226","journal-title":"Mol Ther Oncolytics"},{"issue":"10","key":"12321_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012321","volume":"13","author":"W Li","year":"2025","unstructured":"Li W, Chen J, Li J, Wang S, Chen Z, Zhao L et al (2025) Envirotune-CAR-T: a hypoxia-responsive and glutamine-enhanced CAR-T cell therapy for overcoming tumor microenvironment-mediated suppression. J Immunother Cancer 13(10):e012321","journal-title":"J Immunother Cancer"},{"key":"12321_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002755","author":"H He","year":"2021","unstructured":"He H, Liao Q, Zhao C, Zhu C, Feng M, Liu Z et al (2021) Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-002755","journal-title":"J Immunother Cancer"},{"issue":"4","key":"12321_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100227","volume":"2","author":"P Kosti","year":"2021","unstructured":"Kosti P, Opzoomer JW, Larios-Martinez KI, Henley-Smith R, Scudamore CL, Okesola M et al (2021) Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. Cell Rep Med 2(4):100227","journal-title":"Cell Rep Med"},{"issue":"1","key":"12321_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/srep39833","volume":"7","author":"A Juillerat","year":"2017","unstructured":"Juillerat A, Marechal A, Filhol JM, Valogne Y, Valton J, Duclert A et al (2017) An oxygen sensitive self-decision making engineered CAR T-cell. Sci Rep 7(1):39833","journal-title":"Sci Rep"},{"issue":"1","key":"12321_CR42","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40364-020-00238-9","volume":"8","author":"Q Liao","year":"2020","unstructured":"Liao Q, He H, Mao Y, Ding X, Zhang X, Xu J (2020) Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing. Biomark Res 8(1):56","journal-title":"Biomark Res"},{"issue":"4","key":"12321_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100244","volume":"2","author":"B Prinzing","year":"2021","unstructured":"Prinzing B, Krenciute G (2021) Hypoxia-inducible CAR expression: an answer to the on-target\/off-tumor dilemma? Cell Rep Med 2(4):100244","journal-title":"Cell Rep Med"},{"key":"12321_CR44","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1126\/scitranslmed.abe7378","volume":"13","author":"JH Choe","year":"2021","unstructured":"Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA et al (2021) SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med 13:591","journal-title":"Sci Transl Med"},{"key":"12321_CR45","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1126\/scitranslmed.abd8836","volume":"13","author":"A Hyrenius-Wittsten","year":"2021","unstructured":"Hyrenius-Wittsten A, Su Y, Park M, Garcia JM, Alavi J, Perry N et al (2021) SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci Transl Med 13:591","journal-title":"Sci Transl Med"},{"key":"12321_CR46","doi-asserted-by":"crossref","unstructured":"Murad JP, Christian L, Rosa R, Ren Y, Buckley AJ, Lee EHJ et al (2025) Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery. Nat Biomedical Eng. :1\u201317","DOI":"10.1038\/s41551-025-01509-2"},{"issue":"1","key":"12321_CR47","doi-asserted-by":"publisher","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","volume":"7","author":"OO Yeku","year":"2017","unstructured":"Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ (2017) Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep 7(1):10541","journal-title":"Sci Rep"},{"issue":"1","key":"12321_CR48","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12026-025-09687-6","volume":"73","author":"T Premchandani","year":"2025","unstructured":"Premchandani T, Qutub M, Tatode A, Umekar M, Taksande J, Hussain UM et al (2025) Engineering CAR-T cells for solid tumors: bispecific antigen targeting, tumor microenvironment modulation, and toxicity control. Immunol Res 73(1):135","journal-title":"Immunol Res"},{"issue":"2","key":"12321_CR49","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nri1001","volume":"3","author":"G Trinchieri","year":"2003","unstructured":"Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3(2):133\u2013146","journal-title":"Nat Rev Immunol"},{"key":"12321_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.839783","volume":"13","author":"W Glienke","year":"2022","unstructured":"Glienke W, Dragon AC, Zimmermann K, Martyniszyn-Eiben A, Mertens M, Abken H et al (2022) GMP-compliant manufacturing of TRUCKs: CAR T cells targeting GD2 and releasing inducible IL-18. Front Immunol 13:839783","journal-title":"Front Immunol"},{"issue":"1","key":"12321_CR51","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12967-022-03626-x","volume":"20","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zhuang Q, Wang F, Zhang C, Xu C, Gu A et al (2022) Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy. J Translational Med 20(1):432","journal-title":"J Translational Med"},{"issue":"1","key":"12321_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003633","volume":"10","author":"J Hu","year":"2022","unstructured":"Hu J, Yang Q, Zhang W, Du H, Chen Y, Zhao Q et al (2022) Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. J Immunother Cancer 10(1):e003633","journal-title":"J Immunother Cancer"},{"key":"12321_CR53","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133977","author":"N Tang","year":"2020","unstructured":"Tang N, Cheng C, Zhang X, Qiao M, Li N, Mu W et al (2020) TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.133977","journal-title":"JCI Insight"},{"issue":"4","key":"12321_CR54","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM et al (2022) PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med 28(4):724\u2013734","journal-title":"Nat Med"},{"issue":"10","key":"12321_CR55","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1016\/j.ymthe.2024.07.020","volume":"32","author":"N Li","year":"2024","unstructured":"Li N, Rodriguez JL, Yin Y, Logun MT, Zhang L, Yu S et al (2024) Armored bicistronic CAR T cells with dominant-negative TGF-\u03b2 receptor II to overcome resistance in glioblastoma. Mol Ther 32(10):3522\u20133538","journal-title":"Mol Ther"},{"issue":"7","key":"12321_CR56","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1016\/j.ymthe.2024.05.006","volume":"32","author":"Y Shi","year":"2024","unstructured":"Shi Y, Kotchetkov IS, Dobrin A, Hanina SA, Rajasekhar VK, Healey JH et al (2024) GLUT1 overexpression enhances CAR T cell metabolic fitness and anti-tumor efficacy. Mol Ther 32(7):2393\u20132405","journal-title":"Mol Ther"},{"issue":"3","key":"12321_CR57","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006522","volume":"11","author":"K Lontos","year":"2023","unstructured":"Lontos K, Wang Y, Joshi SK, Frisch AT, Watson MJ, Kumar A et al (2023) Metabolic reprogramming via an engineered PGC-1\u03b1 improves human chimeric antigen receptor T-cell therapy against solid tumors. J Immunother Cancer 11(3):e006522","journal-title":"J Immunother Cancer"},{"issue":"10","key":"12321_CR58","doi-asserted-by":"publisher","first-page":"R453","DOI":"10.1016\/j.cub.2014.03.034","volume":"24","author":"M Schieber","year":"2014","unstructured":"Schieber M, Chandel NS (2014) ROS function in redox signaling and oxidative stress. Curr Biol 24(10):R453\u2013R462","journal-title":"Curr Biol"},{"issue":"544","key":"12321_CR59","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aat6753","volume":"11","author":"AI Salter","year":"2018","unstructured":"Salter AI, Ivey RG, Kennedy JJ, Voillet V, Rajan A, Alderman EJ et al (2018) Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci Signal 11(544):eaat6753","journal-title":"Sci Signal"},{"issue":"625","key":"12321_CR60","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aay8248","volume":"13","author":"BI Philipson","year":"2020","unstructured":"Philipson BI, O\u2019Connor RS, May MJ, June CH, Albelda SM, Milone MC (2020) 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling. Sci Signal 13(625):eaay8248","journal-title":"Sci Signal"},{"key":"12321_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115973","author":"MS Cook","year":"2025","unstructured":"Cook MS, King E, Flaherty KR, Siddika K, Papa S, Benjamin R et al (2025) CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients. Cell Rep. https:\/\/doi.org\/10.1016\/j.celrep.2025.115973","journal-title":"Cell Rep"},{"issue":"3","key":"12321_CR62","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K et al (2018) A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med 24(3):352\u2013359","journal-title":"Nat Med"},{"issue":"52","key":"12321_CR63","doi-asserted-by":"publisher","first-page":"eaba5962","DOI":"10.1126\/sciimmunol.aba5962","volume":"5","author":"Z-C Ding","year":"2020","unstructured":"Ding Z-C, Shi H, Aboelella NS, Fesenkova K, Park E-J, Liu Z et al (2020) Persistent STAT5 activation reprograms the epigenetic landscape in CD4\u2009+\u2009T cells to drive polyfunctionality and antitumor immunity. Sci Immunol 5(52):eaba5962","journal-title":"Sci Immunol"},{"issue":"9","key":"12321_CR64","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1038\/s41375-019-0417-9","volume":"33","author":"MR Collinson-Pautz","year":"2019","unstructured":"Collinson-Pautz MR, Chang W-C, Lu A, Khalil M, Crisostomo JW, Lin P-Y et al (2019) Constitutively active MyD88\/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies. Leukemia 33(9):2195\u20132207","journal-title":"Leukemia"},{"key":"12321_CR65","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.136093","author":"B Prinzing","year":"2020","unstructured":"Prinzing B, Schreiner P, Bell M, Fan Y, Krenciute G, Gottschalk S (2020) MyD88\/CD40 signaling retains CAR T cells in a less differentiated state. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.136093","journal-title":"JCI Insight"},{"issue":"11","key":"12321_CR66","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1158\/2159-8290.CD-17-0263","volume":"7","author":"M Mata","year":"2017","unstructured":"Mata M, Gerken C, Nguyen P, Krenciute G, Spencer DM, Gottschalk S (2017) Inducible activation of MyD88 and CD40 in CAR T cells results in controllable and potent antitumor activity in preclinical solid tumor models. Cancer Discov 7(11):1306\u201319","journal-title":"Cancer Discov"},{"key":"12321_CR67","unstructured":"Weidong Han D (2017) Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2(HER-2) Positive Advanced Solid Tumors (CART-HER-2)"},{"key":"12321_CR68","unstructured":"Colleen Annesley SCsH (2024) HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent\/Refractory Pediatric CNS Tumors"},{"key":"12321_CR69","unstructured":"Wweidong Han D (2020) Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors"},{"key":"12321_CR70","unstructured":"Hospital R Anti-GPC3 CAR T for Treating Patients With Advanced HCC 2019"},{"key":"12321_CR71","unstructured":"Zhang Z. GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression. 2024."},{"key":"12321_CR72","unstructured":"Weidong Han PD. CD73\/AXL Targeted HypoSti.CAR-T Cells in CD73\/AXL Positive Advanced\/Metastatic Solid Tumors. 2025."},{"key":"12321_CR73","unstructured":"Cheng C. Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer. 2023."},{"key":"12321_CR74","unstructured":"Babinec C. Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells. 2024."},{"key":"12321_CR75","unstructured":"Cheng C. Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells. 2024."},{"key":"12321_CR76","unstructured":"Colleen Annesley SCsH. EGFR806 CAR T Cell Immunotherapy for Recurrent\/Refractory Solid Tumors in Children and Young Adults. 2025."},{"key":"12321_CR77","doi-asserted-by":"crossref","unstructured":"Angioni R, S\u00e1nchez-Rodr\u00edguez R, Viola A, Molon B. TGF-\u03b2 in cancer: metabolic driver of the tolerogenic crosstalk in the tumor microenvironment.Cancers. 2021;13(3):401.","DOI":"10.3390\/cancers13030401"},{"issue":"6","key":"12321_CR78","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J, Liu D, Qin Y, Ge S et al (2022) Claudin18. 2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med 28(6):1189\u201398","journal-title":"Nat Med"},{"key":"12321_CR79","doi-asserted-by":"crossref","unstructured":"Thistlethwaite FC, Gilham DE, Guest RD, Rothwell DG, Pillai M, Burt DJ, et al.The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunology, Immunotherapy. 2017;66(11):1425-36.","DOI":"10.1007\/s00262-017-2034-7"},{"issue":"1","key":"12321_CR80","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12943-024-01952-w","volume":"23","author":"Y Wang","year":"2024","unstructured":"Wang Y, Buck A, Piel B, Zerefa L, Murugan N, Coherd CD et al (2024) Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects. Mol Cancer 23(1):56","journal-title":"Mol Cancer"},{"issue":"1","key":"12321_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61858-z","volume":"16","author":"F Birocchi","year":"2025","unstructured":"Birocchi F, Almazan AJ, Parker A, Bouffard AA, Goncalves S, Kelly C et al (2025) On-target off-tumor toxicity of claudin18. 2-directed CAR-T cells in preclinical models. Nat Commun 16(1):9650","journal-title":"Nat Commun"},{"key":"12321_CR82","doi-asserted-by":"crossref","unstructured":"Zhang Y, Li Y, Cao W, Wang F, Xie X, Li Y, et al. Single-cell analysis of target antigens of CAR-T reveals a potential landscape of \u201con-target, off-tumor toxicity\u201d.Frontiers in immunology. 2021;12:799206.","DOI":"10.3389\/fimmu.2021.799206"},{"issue":"19","key":"12321_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196124","volume":"12","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Qin D, Shou AC, Liu Y, Wang Y, Zhou L (2023) Exploring CAR-T cell therapy side effects: mechanisms and management strategies. J Clin Med 12(19):6124","journal-title":"J Clin Med"},{"key":"12321_CR84","doi-asserted-by":"crossref","unstructured":"Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone marrow transplantation. 2021;56(3):552\u2009\u2013\u200966.","DOI":"10.1038\/s41409-020-01134-4"},{"issue":"10","key":"12321_CR85","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002755","volume":"9","author":"H He","year":"2021","unstructured":"He H, Liao Q, Zhao C, Zhu C, Feng M, Liu Z et al (2021) Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy. J Immunother Cancer 9(10):e002755","journal-title":"J Immunother Cancer"},{"key":"12321_CR86","doi-asserted-by":"crossref","unstructured":"Bigos KJ, Quiles CG, Lunj S, Smith DJ, Krause M, Troost EG, et al. Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours. Frontiers in oncology. 2024;14:1331355.","DOI":"10.3389\/fonc.2024.1331355"},{"key":"12321_CR87","doi-asserted-by":"crossref","unstructured":"Hompland T, Fjeldbo CS, Lyng H. Tumor hypoxia as a barrier in cancer therapy:why levels matter. Cancers. 2021;13(3):499.","DOI":"10.3390\/cancers13030499"},{"key":"12321_CR88","doi-asserted-by":"crossref","unstructured":"Zheng L, Kelly CJ, Colgan SP. Physiologic hypoxia and oxygen homeostasis in the healthy intestine. A review in the theme: cellular responses to hypoxia. American Journal of Physiology-Cell Physiology. 2015;309(6):C350-C60.","DOI":"10.1152\/ajpcell.00191.2015"},{"key":"12321_CR89","doi-asserted-by":"crossref","unstructured":"Shen H, Ojo OA, Ding H, Mullen LJ, Xing C, Hossain MI, et al. HIF1\u03b1-regulated glycolysis promotes activation-induced cell death and IFN-\u03b3 induction in hypoxic T cells. Nat Commun. 2024;15(1):9394.","DOI":"10.1038\/s41467-024-53593-8"},{"key":"12321_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66737-1","author":"R Murray","year":"2025","unstructured":"Murray R, Chowdhury MR, Botticello-Romero NR, Desai K, Chilakapati SR, Chong B et al (2025) Multiplex gene-editing strategy to engineer allogeneic EGFR-targeting CAR T-cells with improved efficacy against solid tumors. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-025-66737-1","journal-title":"Nat Commun"},{"key":"12321_CR91","doi-asserted-by":"crossref","unstructured":"Giorgioni L, Ambrosone A, Cometa MF, Salvati AL, Nistic\u00f2 R, Magrelli A. Revolutionizing CAR T-Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility. International journal of molecular sciences. 2024;25(19):10365.","DOI":"10.3390\/ijms251910365"},{"key":"12321_CR92","doi-asserted-by":"crossref","unstructured":"Gupta D, Shaz B. Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility. Journal of Translational Medicine. 2025;23(1):507.","DOI":"10.1186\/s12967-025-06400-x"},{"key":"12321_CR93","doi-asserted-by":"crossref","unstructured":"Todd VM, Vecchi LA, 3rd, Clements ME, Snow KP, Ontko CD, Himmel L, et al. Hypoxia inducible factor signaling in breast tumors controls spontaneous tumor dissemination in a site-specific manner. Communications biology. 2021;4(1):1122.","DOI":"10.1038\/s42003-021-02648-3"},{"key":"12321_CR94","doi-asserted-by":"crossref","unstructured":"Donlon N, Power R, Hayes C, Reynolds J, Lysaght J. Radiotherapy, immunotherapy,and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity. Cancer letters. 2021;502:84\u201396.","DOI":"10.1016\/j.canlet.2020.12.045"},{"key":"12321_CR95","doi-asserted-by":"crossref","unstructured":"Ponterio E, Haas TL, De Maria R. Oncolytic virus and CAR-T cell therapy in solid tumors. Frontiers in immunology. 2024;15:1455163.","DOI":"10.3389\/fimmu.2024.1455163"},{"issue":"6","key":"12321_CR96","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R et al (2020) Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med 382(6):545\u201353","journal-title":"N Engl J Med"},{"key":"12321_CR97","doi-asserted-by":"crossref","unstructured":"Chen Y, Yu Z, Tan X, Jiang H, Xu Z, Fang Y, et al. CAR-macrophage: A new immunotherapy candidate against solid tumors. Biomedicine & Pharmacotherapy. 2021;139:111605.","DOI":"10.1016\/j.biopha.2021.111605"},{"key":"12321_CR98","doi-asserted-by":"crossref","unstructured":"Wu Z, Boen J, Jindal S, Basu S, Bieniosek M, He S, et al. Spatial multi-omics and deep learning reveal fingerprints of immunotherapy response and resistance in hepatocellular carcinoma. bioRxiv. 2025.","DOI":"10.1101\/2025.06.11.656869"},{"issue":"17","key":"12321_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172898","volume":"17","author":"S Rafii","year":"2025","unstructured":"Rafii S, Mukherji D, Komaranchath AS, Khalil C, Iqbal F, Abdelwahab SI et al (2025) Advancing CAR T-cell therapy in solid tumors: current landscape and future directions. Cancers 17(17):2898","journal-title":"Cancers"},{"key":"12321_CR100","doi-asserted-by":"crossref","unstructured":"Li W, Zhao D, Chen M, Yan X. Emerging advances in CAR-T therapy for solid tumors:latest clinical trial updates from 2025 ASCO annual meeting. Journal of Hematology& Oncology. 2025;18(1):104.","DOI":"10.1186\/s13045-025-01760-9"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12321-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12321-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12321-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:03:33Z","timestamp":1784120613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12321-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12321"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12321-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"29 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u2018Not applicable.\u2019","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u2018Not applicable.\u2019","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u2018Not applicable.\u2019","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AI tools were employed for language editing purposes only. The authors take full responsibility for the scientific accuracy and originality of the manuscript.","order":5,"name":"Ethics","label":"AI use declaration","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u2018Not applicable.\u2019","order":6,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1163"}}